PET/CT in the management of thyroid cancers.

Journal Article (Journal Article;Review)

OBJECTIVE: Thyroid cancer is the most common endocrine cancer. This review evaluates the established use of (18)F-FDG PET/CT in papillary, follicular, Hürthle cell, anaplastic, and medullary thyroid cancers. The significance of incidental diffuse and focal thyroid FDG uptake is discussed. The evolving value of non-FDG radiotracers, including (124)I, (18)F-dihydroxyphenylalanine, and (68)Ga somatostatin analogs, is summarized. CONCLUSION: PET/CT is a valuable imaging test, in the appropriate clinical context, for the management of thyroid cancers.

Full Text

Duke Authors

Cited Authors

  • Marcus, C; Whitworth, PW; Surasi, DS; Pai, SI; Subramaniam, RM

Published Date

  • June 2014

Published In

Volume / Issue

  • 202 / 6

Start / End Page

  • 1316 - 1329

PubMed ID

  • 24848831

Electronic International Standard Serial Number (EISSN)

  • 1546-3141

Digital Object Identifier (DOI)

  • 10.2214/AJR.13.11673


  • eng

Conference Location

  • United States